Eucomed: Co-ordination, not centralisation, is key to sustainable EU
This article was originally published in SRA
What healthcare products will be available to which patients, at what speed and at what level of control? And can Europe afford what it really wants? These are the fundamental questions testing Europe's regulatory experts. John Wilkinson and John Brennan of European medtech industry association Eucomed believe co-ordination among competent authorities is the answer to creating a sustainable system that will last for the next 15-20 years. They explained why to Amanda Maxwell.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
It seems to be game over for anyone who might have been hoping the European Commission would do a U-turn on its decision to use the Italian CND nomenclature as the basis for communication in Eudamed, instead of the well-established GMDN. But GMDN is strong in its resolve to remain a vital global nomenclature service.
2020 is not getting off to a good start for manufacturers needing to comply with the EU’s new Medical Device Regulation on 26 May 2020. The European Commission’s latest document seems to confirm industry’s fears about the ability of the EU’s medtech system to be ready in time.